A woman holds a GLP-1 Injection pen with the cap off.

Ozempic cuts down calorie intake for at least a year, even if hunger returns, trial finds

People taking semaglutide for weight loss continued to consume fewer calories and maintained significant weight loss after 60 weeks, even as some feelings of hunger gradually returned, according to a new Penn Medicine study. Researchers say the findings show the medication remains effective over the long term despite changes in appetite perception. “Our findings show that even when people feel some of those sensations returning, semaglutide continues to help them eat,” said Jena Shaw Tronieri, PhD, a senior research investigator at the Center for Weight and Eating Disorders.

•

PMOS (formerly PCOS) may quadruple risk of heart attack, stroke

Polyendocrine metabolic ovarian syndrome (PMOS), previously referred to as polycystic ovarian syndrome (PCOS), is linked to an increased risk of heart disease, heart attacks, and strokes, according to Penn Medicine research. Clinicians should be sure to carefully monitor the cardiovascular health of women with PMOS, said study author Anuja Dokras, MD, MHCI, PhD, director of the Penn PMOS Center and the Founders Professor of Obstetrics and Gynecology.

Scientists uncover a major biological clue behind anorexia relapse

A new Translational Psychiatry study—examining ghrelin, a hormone that signals hunger, and LEAP2, a protein that blocks ghrelin’s effects—may help explain why many people with anorexia nervosa struggle to maintain recovery after treatment. “Instead of solely relying on weight as a treatment outcome, future work could allow us to consider the possibility of examining changes in hormonal (the ghrelin/LEAP2 signaling) and cognitive function as indicators of treatment outcome and likelihood of long-term remission,” said Rebecca Boswell, PhD, director of the Princeton Center for Eating Disorders at Princeton Health.

YMCA hosts over 700 campers for “Let Your Colors Shine” celebration and field day

More than 700 campers from 17 River Crossing YMCA summer camp programs across Pennsylvania and New Jersey gathered at Deer Path Park in Flemington, N.J., for the YMCA’s third annual “Let Your Colors Shine” field day. The event featured sports, arts and crafts, team-building activities, and a visit from the Three Bridges Fire Department, which helped campers cool off with a water spray from a fire truck. Supported by community sponsors including Doylestown Health, the celebration encouraged friendship, confidence, and self-expression while advancing River Crossing YMCA’s mission of youth development, healthy living, and social responsibility.

New target, new hope? Early trial validates FcRH5 in multiple myeloma

For patients with relapsed or refractory multiple myeloma, resistance to treatment is almost inevitable. Every new therapeutic target expands future options. A Phase I trial published in Nature Medicine offers the first clinical evidence that FcRH5 is a viable target. The multicenter study was led by Adam Cohen, MD, a professor of Hematology-Oncology and director of Myeloma Immunotherapy, with international collaborators.

•

Breast cancer breakthroughs: Lifestyle factors and new treatments highlighted at ASCO 2026

Elizabeth McDonald, MD, PhD, a professor of Radiology and practicing breast radiologist in the Abramson Cancer Center, explained the key findings from a study she presented at the 2026 ASCO Annual Meeting on the relationship between GLP-1s and breast cancer.

•

Bucks County classic bike race returning to Doylestown for 22nd year

The Bucks County Classic will return to Doylestown on Sept. 13 for its 22nd year, bringing professional and amateur cyclists from across the country to compete on a 1.4-mile closed-course circuit through the borough. The event features the Penn Medicine Doylestown Health Pro Women’s Race and draws thousands of spectators to downtown Doylestown. In addition to the races, attendees can enjoy the Doylestown Arts Festival, local food vendors, live entertainment, and family-friendly activities, including a free community ride and children’s races, highlighting the strong community spirit that makes the event unique.

The latest on social media
An illustration of researchers below text that reads: What happens when Alzheimer’s plaques are removed? A rare autopsy study reveals new findings in human brain tissue.

Penn Medicine on Facebook

A rare look inside the human brain is offering new answers on Alzheimer’s disease. In a ground-breaking study published in JAMA, Penn Medicine researchers analyzed the brain of a deceased clinical trial participant to see how clearing amyloid plaques impacts disease progression. The findings were stark: areas where therapy successfully cleared amyloid had minimal damage and tau tangles, while neighboring regions with leftover amyloid showed significant inflammation andneurodegeneration. This side-by-side evidence suggests that early, widespread amyloid clearance may help stop tau accumulation—offering a crucial blueprint for slowing memory loss and cognitive decline.

Published by the Penn Medicine Department of Communications

Debbie Foster / Interim Associate Vice President for Communications, Penn Medicine

Carol Berman / Senior News Director, Penn Medicine

Office: 215-662-2560

Visit us online:

Please note: Materials included in this message are for internal distribution only. Some materials may be protected by copyright law. Such materials include articles and/or broadcast segments provided to Penn Medicine by media monitoring services. If you wish to post or reuse these materials, you must obtain permission from the original publisher. Wall Street Journal articles are available to paid subscribers only. Communications can provide copies of articles upon request.

To ensure that you will receive these emails, please add [email protected] to your Safe Senders list.

Copyright © 2026 Penn Medicine, All rights reserved. |

facebook
twitter